Benzo[a]pyrene diol epoxide suppresses retinoic acid receptor-β2 expression by recruiting DNA (cytosine-5-)-methyltransferase 3A by Ye, Fei & Xu, Xiao-Chun
Ye and Xu Molecular Cancer 2010, 9:93
http://www.molecular-cancer.com/content/9/1/93
Open Access SHORT COMMUNICATION
BioMed  Central
© 2010 Ye and Xu; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Short communication Benzo[a]pyrene diol epoxide suppresses retinoic 
acid receptor-β2 expression by recruiting DNA 
(cytosine-5-)-methyltransferase 3A
Fei Ye and Xiao-Chun Xu*
Abstract
Tobacco smoke is an important risk factor for various human cancers, including esophageal cancer. How benzo 
[a]pyrene diol epoxide (BPDE), a carcinogen present in tobacco smoke as well as in environmental pollution, induces 
esophageal carcinogenesis has yet to be defined. In this study, we investigated the molecular mechanism responsible 
for BPDE-suppressed expression of retinoic acid receptor-beta2 (RAR-β2) in esophageal cancer cells. We treated 
esophageal cancer cells with BPDE before performing methylation-specific polymerase chain reaction (MSP) to find 
that BPDE induced methylation of the RAR-β2 gene promoter. We then performed chromatin immunoprecipitation 
(ChIP) assays to find that BPDE recruited genes of the methylation machinery into the RAR-β2 gene promoter. We found 
that BPDE recruited DNA (cytosine-5-)-methyltransferase 3 alpha (DNMT3A), but not beta (DNMT3B), in a time-
dependent manner to methylate the RAR-β2 gene promoter, which we confirmed by reverse transcription-polymerase 
chain reaction (RT-PCR) analysis of the reduced RAR-β2 expression in these BPDE-treated esophageal cancer cell lines. 
However, BPDE did not significantly change DNMT3A expression, but it slightly reduced DNMT3B expression. DNA 
methylase inhibitor 5-aza-2'-deoxycytidine (5-Aza) and DNMT3A small hairpin RNA (shRNA) vector antagonized the 
effects of BPDE on RAR-β2 expressions. Transient transfection of the DNMT3A shRNA vector also antagonized BPDE's 
effects on expression of RAR-β2, c-Jun, phosphorylated extracellular signal-regulated protein kinases 1/2 (ERK1/2), and 
cyclooxygenase-2 (COX-2), suggesting a possible therapeutic effect. The results of this study form the link between the 
esophageal cancer risk factor BPDE and the reduced RAR-β2 expression.
Findings
Tobacco smoke is an important cause of human cancers,
as it contains more than 60 carcinogens [1-4], which are
major risk factors for cancers of the head and neck, lung,
esophagus, pancreas, and bladder [5-9]. Benzo [a]pyrene
diol epoxide (BPDE), a carcinogen present in tobacco
smoke and environmental pollution, has been shown to
induce gene mutations (such as in p53 and KRAS genes)
in vitro [10-13]. Previously, we identified and cloned sev-
eral BPDE-binding genes (such as ATM and BRCA2) and
the cytosine-phosphate-guanine (CpG) islands of various
gene promoters [14]. Cigarette smoke has been shown to
cause morphologic changes and the loss of retinoic acid
receptor-beta2 (RAR-β2) expression in the lung tissues of
experimental animals [15]. Cigarette smoke, specifically
the tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyri-
dyl)-1-butanone, has also been shown to induce the
methylation of the RAR-β2 gene promoters in murine
lung cancer models [16]. We have also previously shown
that RAR-β2 expression is suppressed in premalignant
and malignant esophageal cells [17-19]. Consequently,
expression of epidermal growth factor receptor (EGFR),
extracellular signal-regulated protein kinases 1/2 (ERK1/
2), activated protein-1 (AP-1), and cyclooxygenase-2
(COX-2) are induced by BPDE [19]. Numerous studies
have demonstrated that RAR-β2 expression is frequently
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and progressively lost in premalignant and malignant tis-
sues of the head and neck, lung, esophagus, pancreas,
mammary gland, prostate, and other sites [20-22]. Lost
expression of RAR-β2 in these various human cancers has
been shown to be due to hypermethylation of its gene
promoter [23-27]. However, it is still unknown if, and if
so, how BPDE suppresses the expression of RAR-β2 and
induces methylation of its gene promoter.
In this study, we first confirmed our previous finding
[17,19] that BPDE treatment inhibited RAR-β2 expression
and after 24 h BPDE treatment, RAR-β2 was reexpressed
(Figure 1A) and then we showed that BPDE induced the
methylation of the RAR-β2 gene promoter and in 24 h
BPDE treatment, some DNA still remains methylated
(Figure 1B). Sequencing data from methylation-specific
polymerase chain reaction (MSP) products confirmed
thymine (T)-to-cytosine (C) transitions, indicating that
BPDE induced methylation of the RAR-β2 gene promoter
(Figure 1C). The reason for reexpression of RAR-β2 after
24 h BPDE treatment may be because of BPDE-activated
DNA repair mechanism and in our previous paper, we
showed that BPDE treatment induced ATM expression,
an early protein in the DNA repair pathway after esopha-
geal cancer cells were insulted by BPDE and that A TM
expression was associated with tobacco smoke exposure
in esophageal cancer tissues [14,28]. Next, we determined
the underlying molecular mechanism responsible for
BPDE-induced RAR-β2  promoter methylation by per-
forming a chromatin immunoprecipitation (ChIP) assay
with anti-BPDE antibodies and then a Western blotting
analysis of DNA (cytosine-5-)-methyltransferase 3 alpha
(DNMT3A) and beta (DNMT3B) expression and a poly-
merase chain reaction (PCR) analysis of RAR-β2 gene
promoter expression. The immunoprecipitated protein
showed that BPDE recruited the DNMT3A protein, but
not the DNMT3B protein, to RAR-β2 gene promoter sites
in a time-dependent manner (Figure 2A). The immuno-
precipitated DNA confirmed that BPDE and DNMT3A
bind to the RAR-β2 gene promoter. Although RAR-β2 was
reexpressed 24 h after BPDE treatment, there were
detectable levels of methylated DNA (Figure 1B) that may
c o n t r i b u t e  t o  w e a k e r  D N M T 3 a - b i n d i n g  t o  t h e  RA R - β 2
gene promoter in Figure 2A. However, we found that
BPDE did not significantly change the expression levels of
the DNMT3A protein, but it did slightly decrease
DNMT3B protein levels (Figure 3), which is similar to a
previous study showed that 24 h treatment with cigarette
smoke significantly downregulated DNMT3B but just
slightly induced DNMT3a expression in lung cancer cells
[29]. Furthermore, we determined that the DNA methy-
lase inhibitor 5-aza-2'-deoxycytidine (5-Aza) and
DNMT3A small hairpin RNA (shRNA) vector antago-
nized the effects of BPDE on the methylation of the RAR-
β2 gene promoter. ChIP assay data showed that 5-Aza
treatment inhibited the recruitment of DNMT3A by
BPDE to the RAR-β2 gene promoter site in BPDE-treated
TE-12 cells (Figure 4A). Northern blot analysis indeed
showed that RAR-β2 mRNA expression was restored in
TE-12 cells after treatment with 5-Aza (Figure 4B). After
these tests, we determined the ability of four DNMT3A
shRNA constructs to knock down DNMT3A expression
and found that DNMT3A shRNA-3 was able to suffi-
ciently knock down expression levels of the DNMT3A
protein (Figure 5A). We therefore performed transient
gene transfection experiments followed by reverse tran-
scription-polymerase chain reaction (RT-PCR) analyses
and found that the knockdown of DNMT3A expression
antagonized the ability of BPDE to suppress RAR-β2
expression (Figure 5B). Consequently, we sought to deter-
mine if knockdown of DNMT3A could antagonize the
effect of BPDE on expression of these genes. We found
that transient transfection with DNMT3A shRNA vector
indeed antagonized BPDE's inhibition of RAR-β2 expres-
sion (Figure 5B) and its upregulation of c-Jun, phosphory-
lated ERK1/2, and COX-2 in BPDE-treated SKGT4 and
TE-3 cells (Figure 6).
Our current findings provide further evidence that
BPDE may play a role in esophageal cancer development
and progression by suppressing RAR-β2 expression. As
mentioned above, numerous studies have demonstrated
that RAR-β2 expression is frequently and progressively
lost in premalignant and malignant tissues and cells [20-
22]. These studies clearly indicate that RAR-β2 functions
as a tumor suppressor gene. RAR-β2  gene promoter
methylation is believed to be responsible for the lost
expression of RAR-β2 in various human cancers, includ-
ing esophageal cancer [20-27]. Lost expression of RAR-β2
and methylation of the RAR-β2 gene promoter have been
used as diagnostic markers of tumorigenesis [22]. For
example, methylation of the RAR-β2 gene promoter has
been found in early-stage breast cancer [23] and has been
detected in the bronchial aspirates of lung cancer patients
at a much higher frequency than in patients with benign
lung disease [24]. Furthermore, the RAR-β2 gene pro-
moter has been detected at a high level of methylation in
esophageal cancer and was found to be associated with
RAR-β2  gene silencing in this disease [25]. Cigarette
smoke has been shown to downregulate RAR-β2 expres-
sion, but not that of RAR-α or RAR-γ in the lungs of fer-
r e t s  [ 1 5 ] .  H o w e v e r ,  t h e  c a u s e  o f  t h i s  l o s t  R A R - β 2
expression or RAR-β2 gene promoter methylation is not
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The current study mechanistically links the esophageal
cancer risk factor BPDE to suppressed RAR-β2 expression
and RAR-β2 gene promoter methylation, which may help
in the development of novel strategies against this deadly
disease by using chemopreventive agents to antagonize
the effects of BPDE on esophageal epithelial cells. Recent
studies have shown that cigarette smoke, specifically the
tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-
1-butanone, reduced RAR-β2  expression or induced
RAR-β2 gene promoter methylation in experimental ani-
Figure 1 Suppression of RAR-β2 expression by BPDE. (A) Northern blotting. Esophageal cancer cell lines TE-3 and TE-12 were grown and treated 
with 1 μM BPDE for up to 24 h. RNA was then isolated from the cells and subjected to Northern blotting analysis of RAR-β2 expression. (B) MSP. Esoph-
ageal cancer cell lines TE-3 and TE-12 were grown and treated with 1 μM BPDE for up to 24 h. Genomic DNA was then isolated from the cells and 
subjected to PCR analysis of RAR-β2 gene promoter methylation. M, methylated RAR-β2 gene promoter; U, unmethylated RAR-β2 gene promoter. (C) 
Sequencing histogram (matching GenBank accession number X56849) of a partial RAR-β2 gene promoter. TE-3 cells were treated with or without 1 
μM BPDE for 12 h, and genomic DNA was extracted and subjected to MSP analysis. The PCR product was then cloned into a TA cloning vector. The 
clones carrying RAR-β2 gene promoter were then sequenced in our institutional DNA sequencing facility. Compared with the controls, BPDE-treated 
cells showed two BPDE-methylated sites. Note: Bisulfite converted all C to T, but methylated C cannot be converted, which is the principle of the MSP 
assay.Ye and Xu Molecular Cancer 2010, 9:93
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mals [16]. Epigallocatechin gallate induced a concentra-
tion- and time-dependent reversal of RAR-β2  gene
promoter methylation in esophageal cancer cell lines,
resulting in the restoration of RAR-β2 expression [30].
The factors known to be associated with aberrant CpG
island methylation include local DNA structure changes,
carcinogen exposure, increased DNA-methyltransferase
activity, and microsatellite instability [31,32]. Tobacco
carcinogens are also known factors in the methylation of
various tumor suppressor genes, including the RAR-β2
gene promoter [33-35]. However, the defined causes of
CpG island methylation in cancer are largely unknown. In
the current study, we found that BPDE recruited
DNMT3A to methylate the RAR-β2 gene promoter and
thus silence its gene expression, which in turn, may con-
tribute to the malignant transformation of esophageal
epithelial cells. Taken together, the results of this study
form the link between the esophageal cancer risk factor
BPDE and the reduced RAR-β2 expression, which may
help in the development of novel strategies against this
now deadly disease by antagonizing the effects of BPDE
on esophageal epithelial cells with anti-methylation
agents.
Materials and methods
Cell culture and drug treatment
Esophageal squamous cancer cell lines TE-3 and TE-12
and adenocarcinoma cell line SKGT4 were grown and
maintained as described elsewhere [17-19]. BPDE was
purchased from Midwest Research Institute (Kansas City,
Figure 2 ChIP assay. Esophageal cancer TE-3 cells were grown and 
treated with 1 μM BPDE for up to 24 h. After that, the cells were fixed 
with formaldehyde for 10 min, and the nuclei were then isolated, son-
icated, and immunoprecipitated with anti-BPDE antibodies. (A) Immu-
noprecipitated protein was subjected to Western blotting analysis of 
DNMT3A and DNMT3B expression. Protein without anti-BPDE anti-
body immunoprecipitation (input) was used as the control. PC, posi-
tive control. (B) Immunoprecipitated DNA was subjected to PCR 
analysis of RAR-β2 gene promoter.
Figure 3 Effect of BPDE on DNMT3A and DNMT3B expression. TE-
3 cells were grown and treated with 1 μM BPDE for up to 24 h. After 
that, total cellular protein was extracted and subjected to Western 
blotting analysis of DNMT3A and DNMT3B expression.
Figure 4 Reversal of BPDE's effect on RAR-β2 expression using 5-
Aza. (A) ChIP assay. Esophageal cancer TE-3 cells were grown and 
treated with or without 1 μM BPDE, 10 μM 5-Aza, or the combination 
of both for 12 h, and the cells were then subjected to ChIP analysis with 
anti-BPDE antibodies. The immunoprecipitated protein was subjected 
to Western blotting analysis of DNMT3A expression. Proteins without 
anti-BPDE antibody immunoprecipitation (input) were used as con-
trols. (B) Northern blotting. Total RNA from TE-3 and TE-12 cells with 
the same treatment was isolated and subjected to Northern blotting 
analysis of RAR-β2 expression.Ye and Xu Molecular Cancer 2010, 9:93
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MO) and 5-Aza from Sigma (St. Louis, MO). The treat-
ment schedules were the same as those used in our previ-
ous studies [17-19].
RNA isolation and Northern blotting
TRIzol reagent (Invitrogen, Carlsbad, CA) was used to
extract RNA from monolayer cultures, and the plasmid
pRC/CMV (Invitrogen, San Diego, CA), which contains
human RAR-β2 cDNA, was prepared for using as the
Northern blotting probe as previously described [36].
MSP and DNA sequencing
DNA isolated from these cells was subjected to MSP
using an MSP kit (Zymed, South San Francisco, CA)
according to the manufacturer's instructions. The prim-
ers used to amplify the methylated RAR-β2 genes were 5'-
TCGAGAACGCGAGCGATTCG-3' and 5'-GACCA-
ATCCAACCGAAACGA-3'. The primers used to amplify
the unmethylated RAR-β2 genes were 5'-TTGAGAAT-
GTGAGTGATTTGA-3' and 5'-AACCAATCCAACCA-
AAACAA-3'. The PCR conditions used were the same as
those described previously [30]. The PCR products were
cloned into the pGEM-T easy vector (Promega, Madison,
WI), amplified, and sequenced in our institutional DNA
sequencing facility with T7 primer.
ChIP assay
The ChIP assay was performed with a kit from Millipore
(Billerica, MA), according to the manufacturer's protocol,
with two clones (#5D11 and 8E11) of anti-BPDE antibod-
ies (Trevigen, Gaithersburg, MD).
Protein extraction and Western blotting
Total cellular protein was isolated for Western blotting as
previously described [17-19]. The antibodies used were
anti-c-Jun/AP-1, anti-DNMT3A (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA), anti-COX-2 (DB Transduction
Laboratories, Lexington, KY), anti-phosphorylated-Erk1/
2, anti-DNMT3B (Cell Signaling Technology, Beverly,
MA), and anti-β-actin antibody (Sigma).
PCR analysis of the RAR-β2 gene promoter
The DNA-protein complex from the ChIP assay was then
subjected to PCR analysis. The primers used for the RAR-
β2  gene promoter were 5'-TCATTTGAAGGTTAG-
CAGCCCGGGTA-3' and 5'-GGAGGCAAATGGCATA-
GAAA-3', which generated a 502-bp PCR product after
35 cycles.
DNMT3A shRNA and transient gene transfection
DNMT3A shRNAs were purchased from OriGene Tech-
nologies (Rockville, MD). They were used for knocking
down DNMT3A expression using Lipofectamine 2000
(Invitrogen) and treated with 0.5 μg/mL of puromycin for
48 h. The total cellular protein from these cells was sub-
jected to Western blotting analysis of DNMT3A expres-
sion, and RNA from duplicate experiments was subjected
to RT -PCR analysis of RAR-β 2 expression as previously
described [36].
5-Aza, 5-aza-2'-deoxycytidine; MSP, methylation-spe-
cific polymerase chain reaction; BPDE, benzo [a]pyrene
diolepoxide; ChIP, chromatin immunoprecipitation;
Figure 5 Effects of DNMT3A shRNA. (A) Knockdown of DNMT3A ex-
pression by DNMT3A shRNA. Esophageal cancer TE-3 cells were grown 
and transiently transfected with DNMT3A 29 mer shRNA constructs in 
pRS vector; 48 h later, total cellular protein was extracted and then sub-
jected to Western blotting analysis of DNMT3A expression. (B) RT-PCR 
analysis of RAR-β2 mRNA expression. Esophageal cancer TE-3 cells were 
grown and transiently transfected with DNMT3A shRNA-3 vector; 48 h 
later, the cells were treated with or without 1 μM BPDE for 12 h and 
RNA was then isolated from the cells and subjected to RT-PCR analysis.
Figure 6 DNMT3A shRNA antagonized BPDE's effect on gene ex-
pression to different levels. Esophageal cancer SKGT-4 and TE3 cells 
were grown and transiently transfected with the empty vector or 
DNMT3A shRNA-3 vector for 48 h. The cells were then treated with or 
without 1 μM BPDE for 12 h, and the total cellular protein was extracted 
and subjected to Western blotting analysis of c-Jun, phosphorylated-
ERK1/2 and COX-2 expression.Ye and Xu Molecular Cancer 2010, 9:93
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CpG, cytosine-phosphate-guanine; DNMT-3A, DNA
(cytosine-5-)-methyltransferase 3 alpha; RT-PCR, reverse
transcription-polymerase chain reaction; RAR-beta2,
retinoic acid receptor-β2.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
XCX developed the experimental design and prepared the manuscript for
publication. FY performed the experiments. Both authors read and approved
the final version of the manuscript.
Acknowledgements
This work was supported in part by National Cancer Institute (NCI) grant R01 
CA117895, a Cancer Center Supporting Grant (CA16672) for our core DNA facil-
ity, and a seed grant from Duncan Family Institute for Cancer Prevention and 
Risk Assessment. We thank the Department of Scientific Publications at The 
University of Texas M. D. Anderson Cancer Center for editing the manuscript.
Author Details
Department of Clinical Cancer Prevention, Unit 1360, The University of Texas M. 
D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, 
USA
References
1. Osborne MR, Crosby NT: Benzopyrenes Cambridge, UK: Cambridge 
University Press; 1987. 
2. Hoffmann D, Hecht SS: Advances in tobacco carcinogenesis.  In 
Chemical Carcinogenesis and Mutagenesis I. Handbook of Experimental 
Pharmacology Volume 94. Edited by: Cooper CS, Grover PL. Berlin, 
Germany: Springer-Verlag; 1990:63-102. 
3. Harvey RG: Polycyclic Aromatic Hydrocarbons: Chemistry and Carcinogenesis 
Cambridge, UK: Cambridge University Press; 1991. 
4. Hecht SS: Cigarette smoking: cancer risks, carcinogens, and 
mechanisms.  Langenbecks Arch Surg 2006, 391:603-613.
5. Smoking, Tobacco, Cancer Program (U.S.): Smoking, Tobacco, and Cancer 
Program: 1985-1989 Status Report U.S. Department of Health and Human 
Services, Public Health Service, National Institutes of Health, National 
Cancer Institute. NIH Publication No. 90-3107. Bethesda, MD; 1990. 
6. Zhang ZF, Kurtz RC, Sun M, Karpeh M Jr, Yu GP, Gargon N, Fein JS, 
Georgopoulos SK, Harlap S: Adenocarcinomas of the esophagus and 
gastric cardia: medical conditions, tobacco, alcohol, and 
socioeconomic factors.  Cancer Epidemiol Biomarkers Prev 1996, 
5:761-768.
7. Gammon MD, Schoenberg JB, Ahsan H, Risch HA, Vaughan TL, Chow WH, 
Rotterdam H, West AB, Dubrow R, Stanford JL, Mayne ST, Farrow DC, Niwa 
S, Blot WJ, Fraumeni JF Jr: Tobacco, alcohol, and socioeconomic status 
and adenocarcinomas of the esophagus and gastric cardia.  J Natl 
Cancer Inst 1997, 89:1277-1284.
8. Tran GD, Sun XD, Abnet CC, Fan JH, Dawsey SM, Dong ZW, Mark SD, Qiao 
YL, Taylor PR: Prospective study of risk factors for esophageal and 
gastric cancers in the Linxian general population trial cohort in China.  
Int J Cancer 2005, 113:456-463.
9. Xu X-C: Risk factors and gene expression in esophageal cancer.  In 
Cancer Epidemiology, Host Susceptibility Factors Volume I. Edited by: Verma 
M. New York: Humana Press; 2009:335-360. 
10. Venkatachalam S, Denissenko MF, Alvi N, Wani AA: Rapid activation of 
apoptosis in human promyelocytic leukemic cells by (+/-)-anti-
benzo[a]pyrene diol epoxide induced DNA damage.  Biochem Biophys 
Res Commun 1993, 197:722-729.
11. Denissenko MF, Pao A, Tang M, Pfeifer GP: Preferential formation of 
benzo[a]pyrene adducts at lung cancer mutational hotspots in p53.  
Science 1996, 274:430-432.
12. Wang D, You L, Sneddon J, Cheng SL, Jamasbi R, Stoner GD: Frameshift 
mutation in codon 176 of the p53 gene in rat esophageal epithelial 
cells transformed by benzo[a]pyrene dihydrodiol.  Mol Carcinog 1995, 
14:84-93.
13. Mass MJ, Jeffers AJ, Ross JA, Nelson G, Galati AJ, Stoner GD, Nesnow S: Ki-
ras oncogene mutations in tumors and DNA adducts formed by 
benz[j]aceanthrylene and benzo[a]pyrene in the lungs of strain A/J 
mice.  Mol Carcinog 1993, 8:186-192.
14. Liang Z, Lippman SM, Kawabe A, Shimada Y, Xu X-C: Identification of 
benzo[a]pyrene diol epoxide-binding DNA fragments using DNA-
immunoprecipitation technique.  Cancer Res 2003, 63:1470-1474.
15. Wang XD, Liu C, Bronson RT, Smith DE, Krinsky NI, Russell M: Retinoid 
signaling and activator protein-1 expression in ferrets given beta-
carotene supplements and exposed to tobacco smoke.  J Natl Cancer 
Inst 1999, 91:60-66.
16. Vuillemenot BR, Pulling LC, Palmisano WA, Hutt JA, Belinsky SA: 
Carcinogen exposure differentially modulates RAR-beta promoter 
hypermethylation, an early and frequent event in mouse lung 
carcinogenesis.  Carcinogenesis 2004, 25:623-629.
17. Song S, Xu XC: Effect of benzo[a]pyrene diol epoxide on expression of 
retinoic acid receptor-beta in immortalized esophageal epithelial cells 
and esophageal cancer cells.  Biochem Biophys Res Commun 2001, 
281:872-877.
18. Li M, Song S, Lippman SM, Zhang XK, Liu X, Lotan R, Xu XC: Induction of 
retinoic acid receptor-β suppresses cyclooxygenase-2 expression in 
esophageal cancer cells.  Oncogene 2002, 21:411-418.
19. Song S, Lippman SM, Zou Y, Ye X, Ajani JA, Xu X-C: Induction of 
cyclooxygenase-2 by benzo[a]pyrene diol epoxide through inhibition 
of retinoic acid receptor-β2 expression.  Oncogene 2005, 24:8268-8276.
20. Soprano DR, Qin P, Soprano KJ: Retinoic acid receptors and cancers.  
Annu Rev Nutr 2004, 24:201-221.
21. Xu X-C: Tumor-suppressive activity of RAR-β2 in cancer.  Cancer Lett 
2007, 253:14-24.
22. Mongan NP, Gudas LJ: Diverse actions of retinoid receptors in cancer 
prevention and treatment.  Differentiation 2007, 75:853-870.
23. Bean GR, Scott V, Yee L, Ratliff-Daniel B, Troch MM, Seo P, Bowie ML, 
Marcom PK, Slade J, Kimler BF, Fabian CJ, Zalles CM, Broadwater G, Baker 
JC Jr, Wilke LG, Seewaldt VL: Retinoic acid receptor-β2 promoter 
methylation in random periareolar fine needle aspiration.  Cancer 
Epidemiol Biomarkers Prev 2005, 14:790-798.
24. Grote HJ, Schmiemann V, Geddert H, Rohr UP, Kappes R, Gabbert HE, 
Bocking A: Aberrant promoter methylation of p16(INK4a), RAR-β2 and 
SEMA3B in bronchial aspirates from patients with suspected lung 
cancer.  Int J Cancer 2005, 116:720-725.
25. Wang Y, Fang MZ, Liao J, Yang GY, Nie Y, Song Y, So C, Xu X-C, Wang LD, 
Yang CS: Hypermethylation-associated inactivation of retinoic acid 
receptor beta in human esophageal squamous cell carcinoma.  Clin 
Cancer Res 2003, 9:5257-5263.
26. Li R, Saito T, Tanaka R, Satohisa S, Adachi K, Horie M, Akashi Y, Kudo R: 
Hypermethylation in promoter region of retinoic acid receptor-beta 
gene and immunohistochemical findings on retinoic acid receptors in 
carcinogenesis of endometrium.  Cancer Lett 2005, 219:33-40.
27. Olasz J, Juhasz A, Remenar E, Engi H, Bak M, Csuka O, Kasler M: RAR beta2 
suppression in head and neck squamous cell carcinoma correlates 
with site, histology and age.  Oncol Report 2007, 18:105-112.
28. Jiang Y, Liang ZD, Wu TT, Cao L, Zhang H, Xu X-C: ATM expression is 
associated with tobacco smoke exposure in esophageal cancer tissues 
and benzo[a]pyrene diol epoxide in cell lines.  Int J Cancer 2007, 
120:91-95.
29. Liu H, Zhou Y, Boggs SE, Belinsky SA, Liu J: Cigarette smoke induces 
demethylation of prometastatic oncogene synuclein-c in lung cancer 
cells by downregulation of DNMT3B.  Oncogene 2007, 26:5900-5910.
30. Fang MZ, Wang Y, Ai N, Hou Z, Sun Y, Lu H, Yang CS: Tea polyphenol (-)-
epigallocatechin-3-gallate inhibits DNA methyltransferase and 
reactivates methylation-silenced genes in cancer cell lines.  Cancer Res 
2003, 63:7563-7570.
31. Issa JP: CpG island methylator phenotype in cancer.  Nat Rev Cancer 
2004, 4:988-993.
32. Di Croce L, Raker VA, Corsaro M, Fazi F, Fanelli M, Faretta M, Fuks F, Lo Coco 
F, Kouzarides T, Nervi C, Minucci S, Pelicci PG: Methyltransferase 
recruitment and DNA hypermethylation of target promoters by an 
oncogenic transcription factor.  Science 2002, 295:1079-1082.
Received: 14 January 2010 Accepted: 28 April 2010 
Published: 28 April 2010
This article is available from: http://www.molecular-cancer.com/content/9/1/93 © 2010 Ye and Xu; licensee BioMed Central Ltd.  This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Molecular Cancer 2010, 9:93Ye and Xu Molecular Cancer 2010, 9:93
http://www.molecular-cancer.com/content/9/1/93
Page 7 of 7
33. Lin RK, Hsieh YS, Lin P, Hsu HS, Chen CY, Tang YA, Lee CF, Wang YC: The 
tobacco-specific carcinogen NNK induces DNA methyltransferase 1 
accumulation and tumor suppressor gene hypermethylation in mice 
and lung cancer patients.  J Clin Invest 2010, 120:521-532.
34. Breton CV, Byun HM, Wenten M, Pan F, Yang A, Gilliland FD: Prenatal 
tobacco smoke exposure affects global and gene-specific DNA 
methylation.  Am J Respirat Crit Care Med 2009, 180:462-467.
35. Oka D, Yamashita S, Tomioka T, Nakanishi Y, Kato H, Kaminishi M, Ushijima 
T: The presence of aberrant DNA methylation in noncancerous 
esophageal mucosae in association with smoking history: a target for 
risk diagnosis and prevention of esophageal cancers.  Cancer 2009, 
115:3412-3426.
36. Xu XC, Liu X, Tahara E, Lippman SM, Lotan R: Expression and up-
regulation of retinoic acid receptor-beta is associated with retinoid 
sensitivity and colony formation in esophageal cancer cell lines.  
Cancer Res 1999, 59:2477-2483.
doi: 10.1186/1476-4598-9-93
Cite this article as: Ye and Xu, Benzo[a]pyrene diol epoxide suppresses 
retinoic acid receptor-?2 expression by recruiting DNA (cytosine-5-)-methyl-
transferase 3A Molecular Cancer 2010, 9:93